Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation

Autor: Oliver Robak, Sylvia Knapp, JM Doehn, Hildegard T. Greinix, Andreas Winkler, Anastasiya Hladik, Zoya Kuzmina
Rok vydání: 2016
Předmět:
Adult
Male
0301 basic medicine
Cancer Research
Transplantation Conditioning
medicine.medical_treatment
Graft vs Host Disease
Hematopoietic stem cell transplantation
Severity of Illness Index
Transplantation
Autologous
03 medical and health sciences
0302 clinical medicine
immune system diseases
hemic and lymphatic diseases
Severity of illness
Genetics
medicine
Humans
Transplantation
Homologous
Prospective Studies
Mortality
Prospective cohort study
Molecular Biology
Serum amyloid P component
biology
business.industry
C-reactive protein
Hematopoietic Stem Cell Transplantation
Cell Biology
Hematology
Middle Aged
Prognosis
medicine.disease
Tissue Donors
Transplantation
Serum Amyloid P-Component
C-Reactive Protein
surgical procedures
operative
030104 developmental biology
Graft-versus-host disease
Acute Disease
Chronic Disease
Immunology
biology.protein
Female
business
Biomarkers
030215 immunology
Zdroj: Experimental Hematology. 44:917-923
ISSN: 0301-472X
Popis: Acute and chronic graft-versus-host-diseases (aGVHD and cGVHD, respectively) are serious complications after hematopoietic stem cell transplantation (HSCT), impairing survival and quality of life. Because the underlying pathomechanism of GVHD is still poorly understood, we investigated the novel inflammatory marker Pentraxin-3 (PTX3) for its potential role in acute and chronic GVHD compared with autologous HSCT and healthy individuals. We collected plasma samples from patients undergoing autologous (n = 12) and allogeneic (n = 28) HSCT and from healthy individuals (n = 15) throughout 7 days before and up to 1 year after HSCT. PTX3 levels in patients with aGVHD were significantly higher (36.4 ± 23.6 ng/mL) than in allogeneic patients without aGVHD (10.4 ± 4.4 ng/mL, p = 0.0001), autologous controls (11.4 ± 6.7 ng/mL, p = 0.001), or healthy individuals (1.9 ± 0.6 ng/mL, p 0.001). PTX3 levels in patients with cGVHD (13.6 ± 6.3 ng/mL) were significantly lower than in allogeneic patients without cGVHD (25.1 ± 13.8 ng/mL, p = 0.04) and higher than in autologous controls (8.9 ± 7.8 ng/mL, p = 0.07) and healthy individuals (1.9 ± 0.6 ng/mL, p 0.001). Severity of aGVHD and cGVHD correlated with PTX3 levels. Rising PTX3 levels after HSCT indicated unfavorable outcome. We show that PTX3 levels correlate with the severity of aGVHD, cGVHD, and-with reservations-survival in patients undergoing allogeneic HSCT.
Databáze: OpenAIRE
Externí odkaz: